269 related articles for article (PubMed ID: 17469317)
1. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
Bijlsma JW; Lems WF; van de Laar MA
Ned Tijdschr Geneeskd; 2007 Apr; 151(14):795-8. PubMed ID: 17469317
[TBL] [Abstract][Full Text] [Related]
2. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
3. The use of NSAIDs in rheumatic disorders 2005: a global perspective.
Kean WF; Buchanan WW
Inflammopharmacology; 2005; 13(4):343-70. PubMed ID: 16354389
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
5. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
7. [Cardiovascular and gastrointestinal risks associated with selective and non-selective NSAIDs].
van den Bemt BJ; Benraad HB; Rasker JJ
Ned Tijdschr Geneeskd; 2007 May; 151(19):1062-7. PubMed ID: 17552414
[TBL] [Abstract][Full Text] [Related]
8. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
10. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
Hinz B; Renner B; Brune K
Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
13. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Chan FK
Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
[TBL] [Abstract][Full Text] [Related]
14. Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile.
Arellano FM; Yood MU; Wentworth CE; Oliveria SA; Rivero E; Verma A; Rothman KJ
Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):861-72. PubMed ID: 17086563
[TBL] [Abstract][Full Text] [Related]
15. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
Strand V
Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
[TBL] [Abstract][Full Text] [Related]
16. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 inhibitors: what went wrong?
James MJ; Cleland LG
Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):89-94. PubMed ID: 16477171
[TBL] [Abstract][Full Text] [Related]
18. [Further definition of the role of COX-2 inhibitors and NSAIDs in patients with nociceptive pain].
Nurmohamed MT
Ned Tijdschr Geneeskd; 2007 Jun; 151(23):1313; author reply 1313-4. PubMed ID: 17624165
[No Abstract] [Full Text] [Related]
19. COX-2 inhibitors: pharmacological data and adverse effects.
Mattia C; Coluzzi F
Minerva Anestesiol; 2005; 71(7-8):461-70. PubMed ID: 16012420
[TBL] [Abstract][Full Text] [Related]
20. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?
Spektor G; Fuster V
Nat Clin Pract Cardiovasc Med; 2005 Jun; 2(6):290-300. PubMed ID: 16265533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]